The amount of information about the negative effects hormone decline and loss has on every system in our body continues to grow. This study continues to address the correlation between estrogen loss during our peri-menopause and menopausal years and the increased risk for Alzheimer's disease. Exerpts are below as well as the link to the full Medscape article. Call today to schedule your free consultation to discuss how bio-identical hormone therapy not only addresses your day to day symptoms but improves your overall health and decreases risks as we age.
-- MedScape Oct 12, 2017
Menopause is associated with metabolic brain changes that may increase the risk for Alzheimer's disease (AD), a small study suggests.
"Our findings show that the loss of estrogen in menopause doesn't just diminish fertility. This study suggests there may be a critical window of opportunity, when women are in their 40s and 50s, to detect metabolic signs of higher Alzheimer's risk and apply strategies to reduce that risk," Lisa Mosconi, PhD, associate director of the Alzheimer's Prevention Clinic at Weill Cornell Medicine in New York City, said in a news release.
"These findings validate earlier preclinical findings and indicate emergence of bioenergetic deficits in perimenopausal and postmenopausal women, suggesting that the optimal window of opportunity for therapeutic intervention in women is early in the endocrine aging process," the investigators note.
The results "provide critical evidence for early changes in the aging female brain that are relevant to the twofold greater lifetime risk in Alzheimer's disease," senior investigator Roberta Diaz Brinton, PhD, from the University of Arizona Health Sciences in Tucson, added in the news release. "Importantly, these results indicate that we know when to intervene in the aging process to divert the potential for developing this devastating disease."
The investigators point out that none of the postmenopausal women in the study were receiving hormone replacement therapy (HRT). Studies have shown that HRT is effective at preserving CMRglc in AD regions, especially if initiated before menopause.
"Our biomarker results support further investigation of the potential efficacy of estrogen-based therapies in preventing decline in brain bioenergetic capacity in women at the perimenopausal stage," the investigators write.
To view the whole article, click the link below.